1. Introduction {#sec1-ijerph-13-00568}
===============

Individuals with perinatally-acquired human immunodeficiency virus type 1 (HIV) infection (PHIV+) are frequently diagnosed and started on antiretroviral therapy (ART) during the first months or years of life. The global expansion in the use of pediatric ART has resulted in a significant decrease in mortality rates among PHIV+, many of whom are now sexually active adolescents or young adults \[[@B1-ijerph-13-00568],[@B2-ijerph-13-00568],[@B3-ijerph-13-00568],[@B4-ijerph-13-00568]\]. Very high viral loads during childhood and frequent family difficulties with sustaining high adherence to complex therapeutic regimens represent barriers to achieving and maintaining viral suppression in this population. An important consequence of this conjunction is the selection of resistant virus while successive changes in ART regimens occur during childhood \[[@B3-ijerph-13-00568],[@B5-ijerph-13-00568],[@B6-ijerph-13-00568],[@B7-ijerph-13-00568],[@B8-ijerph-13-00568]\]. When reaching adolescence, the need for a third line or salvage ART regimen is not rare among PHIV+. On the other hand, it has been observed that these adolescents have reproductive expectations similar to those of HIV-uninfected individuals \[[@B9-ijerph-13-00568],[@B10-ijerph-13-00568]\], and limited therapeutic options for multi-drug resistant virus may affect the management of their treatment during pregnancy \[[@B11-ijerph-13-00568]\].

A resistance mutation is a mutation in a virus gene that allows the virus to become resistant to treatment with a particular antiviral drug. The term was first used in the management of HIV, the first virus in which genome sequencing was routinely used to look for drug resistance. Most antiretroviral drugs target HIV enzymes encoded by specific genes, reverse transcriptase, protease, or integrase. These enzymes are processed protein products of the HIV pol gene, a viral structural protein \[[@B12-ijerph-13-00568]\].

Our main objective was to describe viral suppression and ARV resistance mutations in an ongoing cohort of PHIV+ pregnant adolescents and women in Rio de Janeiro, Brazil.

2. Materials and Methods {#sec2-ijerph-13-00568}
========================

We analyzed pregnancy data among confirmed PHIV+ women followed at a referral unit for prevention of mother-to-child transmission (PMTCT). Sociodemographic and clinical data, including treatment data, were collected routinely upon enrollment and during follow-up. Women with viral load (VL) \> 1000 copies/mL at enrollment underwent HIV genotyping testing using the TRUGENE HIV-1 DNA sequencing platform. This platform detects HIV genomic mutations in the protease and reverse transcriptase regions of HIV, that are the most common mutations found among antiretroviral experienced individuals in our clinical settings \[[@B13-ijerph-13-00568]\]. The genotyping kit is a sequence-based assay target at codons 1--99 at the protease region and codons 40--247 at the reverse transcriptase region. Relevant ARV genotypic mutations were determined using the Stanford database. Descriptive analyses were performed using SPSS 18.0. This study was approved by the local Institutional Review Board (Approval Code 46937015.8.0000.5252).

3. Results {#sec3-ijerph-13-00568}
==========

From February 2011 to August 2014, 630 HIV-infected pregnant women were enrolled in the PMTCT program. Among these, 22 (3.5%) were PHIV+. The median age at enrollment for the 22 PHIV+ was 18.5 years (Interquartile Range (IQR): 17.6--21.0), 71% were non-white, 86% had an AIDS-defining diagnosis according to CDC criteria, and 81% had disclosed their HIV status to the current sexual partner. The median number of years of formal education was nine years (IQR: 6.5--11).

The median age at HIV diagnosis was 8.3 years (IQR: 4.0--13.6), the median age at sexual debut was 16 years (IQR: 14--18), and 71% conceived while using antiretrovirals (ARV). At enrollment, 4/22 (18%) were on their first ART regimen, 8/22 (36%) on their second regimen, and 9/22 (41%) on at least their third ART regimen (1/22 had no ARV data available). Prenatal care was initiated at a median gestational age of 14 weeks (IQR: 9.0--20). At enrollment, 17/22 (77%) had a viral load (VL) \> 50 copies/mL, and 17/22 (77%) had a VL assay result near delivery with 7/17 (41%) having a VL \< 50 copies/mL at that time. Sixteen women had viral genotype testing at prenatal entry, and all received highly active antiretroviral therapy (HAART) during pregnancy. [Table 1](#ijerph-13-00568-t001){ref-type="table"} shows the resistance profiles for these 16 PHIV+ subjects. Among those who had genotyping testing at enrollment, 11/16 (69%) had mutations associated with ARV resistance. The most frequent major mutations found among PHIV+ at enrollment were K103N (8/16, 50%) for NNRTIs; M184V (6/16, 38%), T215 (4/16, 25% ), M41L (3/16, 19%), and D67 (3/16, 19%) for NRTIs, and M46 (3/16, 19%), I54V (2/16, 13%) and V82A (2/16, 13%) for PIs.

All patients with VL \> 50 copies/mL near delivery had a cesarean section. Among those with VL \< 50 copies/mL, three had a vaginal delivery and four had a cesarean section for obstetric indications. There was one spontaneous abortion.

Infants' mean gestational age was 38 weeks (IQR: 37--39), there were four preterm infants (18%). Mean birth weight was 2814 gr (IQR: 2.43--3.17) and mean birth length was 47 cm (IQR = 46--49). None of the infants were HIV-infected.

4. Discussion {#sec4-ijerph-13-00568}
=============

A small proportion of pregnant women followed at our PMTCT unit acquired their HIV infection perinatally, and this analysis updates information available regarding this specific population. The main limitation of our study is the small sample, due to the rarity of this event, however this is a population of significant interest as more perinatally infected individuals have children of their own.

The median age of pregnant PHIV+ was similar to what was recently observed in the United States and Italy \[[@B11-ijerph-13-00568],[@B14-ijerph-13-00568]\]. The median age of 8.3 years at HIV diagnosis was very close to 7.7 years reported for Italian pregnant PHIV+ \[[@B12-ijerph-13-00568]\], but slightly younger than age 10 years which we had observed in 2010 \[[@B4-ijerph-13-00568]\], pointing to a longer exposure time of ART use in the present population.

Among this group of PHIV+, we found a higher prevalence of diagnosis disclosure to sexual partners, as compared to PHIV+ in Africa and the UK/Ireland \[[@B10-ijerph-13-00568],[@B15-ijerph-13-00568]\]. This is a very positive finding, which will likely positively impact the quality of life and outlook for these patients and newly established families.

At enrollment, only 5/22 (23%) of PHIV+ had a VL below 50 copies/mL, but close to delivery this percentage increased to 41%. Our results are comparable to those from a US cohort that found 60% of pregnant PHIV+ with a VL below 400 copies/mL \[[@B11-ijerph-13-00568]\] and worse than a cohort from the United Kingdom where only 33% of PHIV+ pregnant had a viral load above 50 copies/mL near delivery \[[@B14-ijerph-13-00568]\].

Most of our patients have been exposed to at least two ART regimens and the observed suboptimal viral suppression among PHIV+ at enrollment is probably associated with non-adherence to ART and the presence of viral resistance. In a systematic review that included studies published from 1990 to 2011 with 1980 PHIV+ on ART from 26 countries, Sánchez *et al.* \[[@B16-ijerph-13-00568]\] found drug resistance mutations in 78% of PHIV+, higher than the 69% noted in our study. These observations among perinatally-infected populations differ significantly from data in the general population of HIV-infected women. Our own group has reported ART resistance mutations in 15.6% of 231 HIV-infected women during pregnancy \[[@B13-ijerph-13-00568]\]. In our cohort, 8/16 (50%) and 3/16 (19%) had NNRTI and PI resistance mutations, respectively. Data from 211 adolescents in the United Kingdom exposed to ART showed 65% had mutations for NNRTIs, mainly K103N and Y181C, and 26% with mutations for PIs \[[@B3-ijerph-13-00568]\]. K103N mutation is in the reverse transcriptase gene region of HIV-1. It causes the hydrophobic pocket in which the NNRTI binds to inhibit enzyme activity in reverse transcriptase to close by means of a hydrogen bond. K103N is a nonpolymorphic mutation selected in patients receiving NVP and EFV. It reduces NVP and EFV susceptibility by about 50 and 20-fold, respectively \[[@B17-ijerph-13-00568]\]. Similarly, M184V confers high-level resistance to lamivudine, and is a discriminatory mutation. It occurs at or near the binding site of the reverse transcriptase gene, a common feature of mutations that confer resistance to NRTIs \[[@B12-ijerph-13-00568]\]. T215 confers resistance to zidovudine, and is also in the reverse transcriptase gene. It is one of the Thymidine Analog Mutations (TAMs), similarly to M41L, which is also a mutation conferring high level resistance to zidovudine, stavudine and some resistance to didanosine, abacavir and tenofovir. D67 is also an NRTI mutation in the RT gene, which confers resistance to zidovudine and stavudine. M46 is a protease inhibitor mutation associated with resistance to lopinavir/ritonavir and atazanavir/ritonavir. It is an HIV protease gene mutation \[[@B18-ijerph-13-00568]\]. 154 V is a mutation associated with protease inhibitor resistance, particularly nelfinavir \[[@B19-ijerph-13-00568]\]. Like the others, is located in the HIV pol gene. V82A is a mutation also associated with protease inhibitor resistance in the HIV protease region \[[@B20-ijerph-13-00568]\].

The gestational age of infants born to PHIV+ are similar to that described in cohorts in Italy and New York \[[@B12-ijerph-13-00568],[@B21-ijerph-13-00568]\] where the proportions of preterm infants were 38% and 29%, higher than what we observed. Mean birth weight among our patients was higher than in these groups probably due to the smaller proportion of preterm infants.

5. Conclusions {#sec5-ijerph-13-00568}
==============

Despite advances in HIV treatment, ART management during the pregnancies of PHIV+ is especially challenging. New drugs, effective counseling, strategies and interventions targeting patient retention and individualized ART regimens are needed and may be crucial to achieve viral suppression in a highly ART-exposed subpopulation with expected adherence difficulties.

The authors thank Jennifer Read from the National Institutes of Health for the review of English language.

Maria Letícia Cruz elaborated the study, developed the project, supervised the data analysis and interpretation, and coordinated the writing committee of the article. Edwiges Santos worked on study elaboration, data collection and approved the final version of this article. Maria de Lourdes Benamor Teixeira was responsible for quantitative analysis and approved the final version of this article. Monica Poletti and Carolina de Sousa worked on the writing committee and approved the final version of this article. Maria Isabel Gouvea and Karin Nielsen-Saines worked on data analysis and approved the final version of this article. Esaú João worked on study development, data analysis, writing committee and approved the final version of this article.

The authors declare no conflict of interest.

The following abbreviations are used in this manuscript:

PHIV+

perinatally-HIV infected

ARV

Antiretroviral

ART

Antiretroviral therapy

AIDS

Acquired Immunodeficiency Syndrome

HIV

Human Immunodeficiency Virus

VL

Viral load

CDC

Centers for Disease Control and Prevention

IQR

Interquartile range

NNRTI

Non-nucleoside reverse transcriptase inhibitor

PI

Protease inhibitor

TDF

Tenofovir

NFV

Nelfinavir

DDI

Didanosine

RPV

Rilpivirine

ABC

Abacavir

ZVD

Zidovudine

D4T

Estavudine

3TC

Lamivudine

FTC

Emtricitabine

DRV

Darunavir

TPV

Tripanavir

ETV

Etravirine

EFZ

Efavirenz

ATV

Atazanavir

IDV

Indinavir

SQV

Saquinavir

NVP

Nevirapine

FSP

Fosamprenavir

LPV

Lopinavir
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Genotypic resistance mutations identified and antiretroviral resistance profile in pregnant women with perinatally-acquired HIV infection.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient Number   Subtype   Protease Inhibitors (PI)   Reverse Transcriptase Inhibitor Mutations   Resistance Profile                                                                                     
  ---------------- --------- -------------------------- ------------------------------------------- ---------------------------------------- --------------------- ------------- ------------------------- --------------------------------------
  **1**            NR        0                          L10V                                        0                                        0                                                             

  **2**            B         0                          L10V                                        0                                        0                                                             

  **3**            B         0                          0                                           0                                        0                                                             

  **4**            B         0                          K20T A71T                                   M41L M184V T215D                         K101P K103NS Y188HL   TDF\          ABC ZVD D4T DDI           3TC FTC\
                                                                                                                                                                   NFV                                     EFV ETR NVP RVP

  **5**            F1        0                          L10I                                        M184V T215Y                              V90I K103N E138A      DDI\          ABC ZVD D4T               3TC FTC\
                                                                                                                                                                   RPV                                     EFV NVP

  **6**            B         0                          0                                           D67N T69D M184V K219Q                    A98G Y181C H221Y      ABC ZVD D4T   DDI EFV ETR RPV           3TC FTC\
                                                                                                                                                                                                           NVP

  **7**            B         V32I M46I I47A             L10I A71V                                   M41L D67N V75M M184V L210W T215Y K219N   K103N                               ATZ/r DRV/r IDV/r TPV/r   ABC ZVD D4T DDI 3TC FTC TDF EFV NVP\
                                                                                                                                                                                                           FSP/r NFV LPV/r

  **8**            F1        0                          L10V                                        0                                        K103N                                                         EFV NVP

  **9**            B         0                          0                                           0                                        0                                                             

  **10**           B         M46L I54IV V82AV L90LM     L10F L33F G73AG                             M41L T215S K219R                         K103N                 3TC FTC\      ABC DDI TDF\              ZVD D4T\
                                                                                                                                                                   DRV/r         TPV/r                     EFV NVP\
                                                                                                                                                                                                           ATZ/r FSP/r IDV/r LPV/r NFV SQV/r

  **11**           F1        0                          0                                           0                                        K103N V106I                                                   EFV NVP

  **12**           B         M46I I54V L76V V82A        L10V A71V                                   D67N T69N K70R M184V K219Q               0                     TDF\          ABC D4T DDI\              ZVD 3TC FTC\
                                                                                                                                                                   DRV/r TPV/r   ATZ/r SQV/r               FSP/r IDV/r LPV/r NFV

  **13**           B/F       0                          A71V                                        0                                        0                                                             

  **14**           F1        0                          0                                           D67N K70R M184V K219Q                    K103N P225H           TDF           ABC AZT D4T DDI           3TC FTC\
                                                                                                                                                                                                           EFV NVP

  **15**           B         0                          0                                           M184V                                    K103N                 DDI ABC                                 3TC FTC\
                                                                                                                                                                                                           EFV NVP

  **16**           B         0                          0                                           M184V                                    V179D Y188L           ABC\                                    3TC FTC\
                                                                                                                                                                   ETR                                     EFV NVP RPV
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
